Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR39 | O43194 | 1/20 | 0.43 |
| ▸ | PDE5A | O76074 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.39 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31192198 | 1.00 | GPR39 (0.43) | GPR39PDE5APDE4APDE4BPDE4C | |
| SCHEMBL17784680 | 0.92 | FFAR1 (0.44) | NPC1ALDH1A1CYP2D6CYP2C19KDM1A | |
| SCHEMBL5513890 | 0.91 | HTR2C (0.42) | GPR39PDE5APDE4APDE4BPDE4C | |
| SCHEMBL5513885 | 0.91 | HTR2C (0.42) | GPR39PDE5APDE4APDE4BPDE4C | |
| SCHEMBL15130036 | 0.91 | CTSL (0.45) | NPC1CNR2HPGDRAB9A | |
| Water SCHEMBL2649402 | 0.90 | CNR2 (0.38) | GPR39PDE5APDE4APDE4BPDE4C | |
| SCHEMBL10499108 | 0.88 | KDM1A (0.56) | KDM1A | |
| SCHEMBL20070282 | 0.85 | HRH3 (0.49) | — | |
| SCHEMBL27947518 | 0.84 | CTSL (0.41) | NPC1CNR2HPGDRAB9A | |
| SCHEMBL4958459 | 0.83 | MKNK1 (0.39) | NPC1ALDH1A1CYP2D6CYP2C19KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179061-A1 | RIP1 MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd. (KY) | 2025-06-05 | — | — | US | disclosed |
| CN-105189515-B | Furopyridine class as bromine structural domain inhibitor | 葛兰素史克知识产权第二有限公司 | 2018-07-03 | — | — | CN | disclosed |
| CN-108137513-A | Pyrimidine derivatives | ASKA 制药株式会社 | 2018-06-08 | — | — | CN | disclosed |
| CN-107207444-A | Bicyclic compound | 武田药品工业株式会社 | 2017-09-26 | — | — | CN | disclosed |
| EP-2545055-B1 | Imidazo[1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-09 | — | — | EP | disclosed |
| CN-104039944-B | Encapsulated benefit agent | 荷兰联合利华有限公司 | 2017-04-26 | — | — | CN | disclosed |
| CN-106458984-A | 5, 6-disubstituted pyridine-2-carboxamides as cannabinoid receptor agonists | 豪夫迈·罗氏有限公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-105392777-A | Biaryl derivatives as GRP120 agonists | LG LIFE SCIENCES LTD | 2016-03-09 | — | — | CN | disclosed |
| CN-105121436-A | Novel pyridine derivatives | HOFFMANN LA ROCHE | 2015-12-02 | — | — | CN | disclosed |
| US-9102621-B2 | Acyl sulfonamide compounds | PFIZER LIMITED (GB) | 2015-08-11 | — | — | US | disclosed |
| WO-2014060395-A1 | SERINE/THREONINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-04-24 | — | — | WO | disclosed |
| US-8592629-B2 | Sulfonamide derivatives as Nav 1.7 inhibitors | PFIZER LIMITED (GB) | 2013-11-26 | — | — | US | disclosed |
| WO-2013102826-A1 | N-AMINOSULFONYL BENZAMIDES | PFIZER LIMITED (GB) | 2013-07-11 | — | — | WO | disclosed |
| EP-2593432-A1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | Pfizer Limited (GB) | 2013-05-22 | — | — | EP | disclosed |
| US-20130109708-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2013-05-02 | — | — | US | disclosed |
| WO-2012007861-A1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| US-20120010183-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120010247-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-01-12 | — | — | US | disclosed |
| EP-2351743-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-08-03 | — | — | EP | disclosed |
| US-20100311748-A1 | HETEROCYCLIC AMIDES USEFUL FOR THE TREATMENT OF CANCER AND PSORIASIS | ASTRAZENECA AB (SE) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010247-A1 | BICYCLIC COMPOUND | ACACA, CPT1B, ACACB | GPR39 1972/4885PDE5A 1750/4885PDE4A 3278/4885 |
| US-20130109708-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | GPR39 2091/4885PDE5A 2314/4885PDE4A 2977/4885 |
| US-20250179061-A1 | RIP1 MODULATORS, PREPARATIONS, AND USES THEREOF | RIPK1, RIPK2, RIPK3 | GPR39 2649/4885PDE5A 4339/4885PDE4A 3514/4885 |
| US-20120010183-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | GPR39 1639/4885PDE5A 1956/4885PDE4A 1993/4885 |
| US-20100311748-A1 | HETEROCYCLIC AMIDES USEFUL FOR THE TREATMENT OF CANCER AND PSORIASIS | SHH, GLI1, HRH4 | GPR39 371/4885PDE5A 1131/4885PDE4A 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.